Conferences - Results from #9720

EAU 2017: Pure histological variants are associated with poor survival at radical cystectomy in patients with bladder cancer March 26, 2017

EAU 2017: Efficacy of long acting sandostatin on reducing mucus production in patients with ileal neobladder March 26, 2017

EAU 2017: Increasing use of incontinent urinary diversion: A total population analysis of radical cystectomies in Germany from 2006 to 2013 March 26, 2017

EAU 2017: The use of antibiotic prophylaxis in patients undergoing radical cystectomy for bladder cancer March 26, 2017

EAU 2017: 20-gene expression signature to predict lymph node positive disease at radical cystectomy for muscle-invasive bladder cancer: Not validated March 26, 2017

EAU 2017: Can pre-operative functional status (FS) or gait velocity (GV) replace cardiopulmonary exercise testing (CPET) as an independent predictor of survival and complications following radical cystectomy (RC)? March 26, 2017

EAU 2017: The diverse genomic landscape of low-risk prostate cancer March 26, 2017

EAU 2017: Prostate cancer screening in high risk families: Should PSA testing be performed yearly in first degree relatives with baseline PSA ≤1ng/ml? March 26, 2017

EAU 2017: Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic March 25, 2017

EAU 2017: At what age should a PSA-based screening program start? 20-year results from the Göteborg randomized population-based prostate cancer screening study March 25, 2017

EAU 2017: An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial March 25, 2017

EAU 2017: APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT) March 25, 2017

EAU 2017: A national, prospective, non-interventional study (NIS) of nivolumab (BMS-936558) in patients with advanced renal cell carcinoma after prior therapy March 25, 2017

EAU 2017: IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC) March 25, 2017

EAU 2017: PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC) March 25, 2017

EAU 2017: Phase 1b/2 trial of pembrolizumab combination therapy for metastatic castration-resistant prostate cancer (mCRPC) March 25, 2017

EAU 2017: Does imaging improve safety and efficacy of primary and salvage radiotherapy? March 25, 2017

EAU 2017: When and how to include MRI into active surveillance protocols? March 25, 2017

EAU 2017: Controversies - Focal therapy and the concept of the index lesion: Nonsense March 25, 2017

EAU 2017: Controversies - Focal therapy and the concept of the index lesion: Sense March 25, 2017

Page 487 of 594